company background image

MINAPHARM PharmaceuticalsCASE:MIPH Stock Report

Market Cap







25 Oct, 2021


Company Financials
MIPH fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance6/6
Financial Health4/6

MIPH Overview

MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East.

Price History & Performance

Summary of all time highs, changes and price drops for MINAPHARM Pharmaceuticals
Historical stock prices
Current Share Priceج.م103.58
52 Week Highج.م72.50
52 Week Lowج.م132.07
1 Month Change-1.87%
3 Month Change4.17%
1 Year Change38.11%
3 Year Change21.86%
5 Year Change81.72%
Change since IPO1,039.38%

Recent News & Updates

Shareholder Returns

MIPHEG PharmaceuticalsEG Market

Return vs Industry: MIPH exceeded the EG Pharmaceuticals industry which returned -0.2% over the past year.

Return vs Market: MIPH exceeded the EG Market which returned 12.2% over the past year.

Price Volatility

Is MIPH's price volatile compared to industry and market?
MIPH volatility
MIPH Beta0.045
Industry Beta0.85
Market Beta1

Stable Share Price: MIPH is not significantly more volatile than the rest of EG stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: MIPH's weekly volatility (5%) has been stable over the past year.

About the Company

1958n/aWafik El Bardissi

MINAPHARM Pharmaceuticals operates as a pharmaceutical company primarily in Egypt and the Middle East. The company’s products include Angiofox capsules, Artelac and Berberil eye drops; Bon-one, Ciprodiazole, Dumozol, Hydroquine, and Burinex tablets; Chlorhexidine; DICYNONE; Cornerege fluid and ophthalmic gel; Betolvex and Fleboton ampoules; Deponit patches; Dexagel viscous eye drops; Doxiproct plus and Doxiproct ointment; Doxium capules; Broncho-Vaxom capsules for adults and infants; Broncho-Vaxom infant sachets; Effox tablets and capsules; and Extrauma cream, haemorrhoids, and forte gel. It also provides Ferro sanol duodenal, Lipanthyl, Parafon, Ribavirin, Uro-Vaxom, Ursofalk, Ursoplus, Ursotwin, and Ferro Sanol Gyn capsules; Gyno-Pevaryl, Pevisone, Srilane, and Pevaryl cream; Gonapure; Hair Plus Back 2% and 5%; Hair Plus Back Topical FOAM; Lucidril 500; Lucidril, Salofalk, Trimed flu, XerovirinC, and Ossopan tablets; Thrombexx ampoules, cream, and gel; Vidisept N drops; and Luciforte, Oxytocin, Reiferon Retard, and Nausilex ampoules.

MINAPHARM Pharmaceuticals Fundamentals Summary

How do MINAPHARM Pharmaceuticals's earnings and revenue compare to its market cap?
MIPH fundamental statistics
Market Capج.م1.27b
Earnings (TTM)ج.م427.65m
Revenue (TTM)ج.م2.75b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MIPH income statement (TTM)
Cost of Revenueج.م1.64b
Gross Profitج.م1.11b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date


Earnings per share (EPS)34.79
Gross Margin40.39%
Net Profit Margin15.53%
Debt/Equity Ratio62.5%

How did MIPH perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is MINAPHARM Pharmaceuticals undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: MIPH (EGP103.58) is trading above our estimate of fair value (EGP81.44)

Significantly Below Fair Value: MIPH is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: MIPH is good value based on its PE Ratio (3x) compared to the African Pharmaceuticals industry average (15.7x).

PE vs Market: MIPH is good value based on its PE Ratio (3x) compared to the EG market (8.8x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MIPH's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: MIPH is good value based on its PB Ratio (0.7x) compared to the XF Pharmaceuticals industry average (2x).

Future Growth

How is MINAPHARM Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MINAPHARM Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has MINAPHARM Pharmaceuticals performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MIPH has high quality earnings.

Growing Profit Margin: MIPH's current net profit margins (15.5%) are higher than last year (10.2%).

Past Earnings Growth Analysis

Earnings Trend: MIPH's earnings have grown significantly by 33.5% per year over the past 5 years.

Accelerating Growth: MIPH's earnings growth over the past year (98%) exceeds its 5-year average (33.5% per year).

Earnings vs Industry: MIPH earnings growth over the past year (98%) exceeded the Pharmaceuticals industry 10%.

Return on Equity

High ROE: MIPH's Return on Equity (24.8%) is considered high.

Financial Health

How is MINAPHARM Pharmaceuticals's financial position?

Financial Position Analysis

Short Term Liabilities: MIPH's short term assets (EGP2.5B) exceed its short term liabilities (EGP1.7B).

Long Term Liabilities: MIPH's short term assets (EGP2.5B) exceed its long term liabilities (EGP388.9M).

Debt to Equity History and Analysis

Debt Level: MIPH's debt to equity ratio (62.5%) is considered high.

Reducing Debt: MIPH's debt to equity ratio has increased from 39.4% to 62.5% over the past 5 years.

Debt Coverage: MIPH's debt is well covered by operating cash flow (40.3%).

Interest Coverage: MIPH's interest payments on its debt are well covered by EBIT (13.2x coverage).

Balance Sheet


What is MINAPHARM Pharmaceuticals's current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: MIPH's dividend (2.61%) isn’t notable compared to the bottom 25% of dividend payers in the EG market (2.61%).

High Dividend: MIPH's dividend (2.61%) is low compared to the top 25% of dividend payers in the EG market (7.87%).

Stability and Growth of Payments

Stable Dividend: MIPH has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: MIPH has only been paying a dividend for 4 years, and since then payments have fallen.

Current Payout to Shareholders

Dividend Coverage: With its low payout ratio (7.8%), MIPH's dividend payments are thoroughly covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Wafik El Bardissi

no data


Dr. Wafik Saad El Bardissi serves as the Executive Chairman and Chief Executive Officer at Minapharm Pharmaceuticals SAE.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

MINAPHARM Pharmaceuticals's employee growth, exchange listings and data sources

Key Information

  • Name: MINAPHARM Pharmaceuticals
  • Ticker: MIPH
  • Exchange: CASE
  • Founded: 1958
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ج.م1.273b
  • Shares outstanding: 12.29m
  • Website:


  • MINAPHARM Pharmaceuticals
  • El-Bardissi Street
  • 2T Takseem Asmaa Fahmy Street
  • Cairo
  • Egypt


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/25 16:48
End of Day Share Price2021/10/25 00:00
Annual Earnings2020/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.